Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

This study is testing a combination of two hormone-blocking drugs — darolutamide and relugolix — given before surgery (radical prostatectomy) in men with high-risk prostate cancer, to see if shrinking the tumor before removal improves outcomes. **You may be eligible if...** - You are a male 18 or older - You have confirmed high-risk prostate cancer - You are a candidate for surgical removal of the prostate (radical prostatectomy) - Your cancer is at clinical stage T2-T4 and has not spread to distant sites **You may NOT be eligible if...** - You have previously received darolutamide, relugolix, or similar hormone-blocking drugs - You had a heart attack, stroke, or serious heart failure in the past 6 months - You have a known allergy to darolutamide or relugolix - You are taking certain medications (strong CYP3A4 inhibitors/inducers) that cannot be stopped Talk to your doctor to see if this trial is right for you.